绥美凯什么时候可以纳入医保

Suimeike (dolutegravir tablets) is the only three-in-one compound drug containing dolutegravir (DTG). It has the characteristics of high efficacy, good tolerance, high resistance barrier, and few drug interactions. One tablet per day can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and significantly improving their quality of life. Today, let’s take a closer look at when Suimeikai (Doteta Abalamid Tablets) can be included in medical insurance?

According to Medical Companion Travel, Suimeikai (Domitabalamid Tablets) has just been launched in China and has not yet been included in medical insurance, and it is not yet a medical insurance drug. Since Suimeike (Dolutea Paramid Tablets) is an imported original drug in China, it is very expensive and most patients cannot afford it. Therefore, many patients choose Suimeikai (Domitabalamid Tablets), which is available in India. Suimeike (Doteta abalami tablets) produced by the Indian company Emcure, comes in a box of 30 tablets, priced at approximately RMB 1,000. Due to the floating exchange rate, the price cannot be determined. Please consult Medical Travel for specific prices.

The usage and dosage of Suimeikai (Dotiabalamid Tablets) is to be taken under the guidance of a physician with experience in HIV infection. Dosage: Adults and Adolescents (Weighing at least 40kg) For adults and adolescents, the recommended dose of this product is one tablet, once daily. Adults or adolescents whose body weight is less than 40 kg should not be given this product as this product is a fixed-dose tablet and the dose cannot be reduced (see inner package insert for details). We need to be cautious about the usage and dosage of Suimeikai. In addition to strictly following the doctor's instructions, we also need to use it strictly in accordance with the instructions.

Suimeike (dolute abalamide tablets) is suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40kg) infected with human immunodeficiency virus (HIV). HIV-infected patients, regardless of race, should be screened for the HLA-B*5701 allele before starting treatment with abacavir-containing products. If the patient is known to carry the RLA-B*5701 allele, he should not take products containing abacavir.

If the patient misses a dose of Suimeike (Domitabalamid Tablets) and there are more than 4 hours before the next dose, the patient should take this product as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule.

The above is the content of the medical insurance for Suimeikai (Doteta Abalamid Tablets), I hope it can help you!